Menopause

Menopause Startup Lisa Health Launches Its New “Midday” App After Raising $2.5M in Seed Funding

Menopause startup Lisa Health has raised $2.5M in seed funding led by Radical Ventures and announced the launch of its new app, Midday, which has been created in collaboration with Mayo Clinic. Other investors in the round include SRI International and Broadway Angels. The Midday app leverages AI, sensor technology and digital therapeutics to support women on their menopause journey. By 2030,…

Functional Fitness Company P.volve Launches a New Menopause Employee Benefit Program

Functional fitness company P.volve is launching its new  Moving With Menopause program as a benefit employers can offer to their female and trans employees today. P.volve’s menopause program is led by Antonietta Vicario, P.volve’s Head of Menopause Programs and Vice President of Talent and Training, alongside insights from P.volve’s Clinical Advisory Board, whose members include Chief Physical Therapist Dr. Amy Hoover and Dr. Suman Tewari, an…

Bonafide Unveils the Results of Its Second Annual “State of the Menopause” Survey

Bonafide, a women’s healthcare company offering naturally powerful solutions to manage menopause has released its second State of Menopause Study, which aggregates symptoms and treatments, awareness, and societal stereotypes of over 2,000 menopausal aged women in the United States. In an effort to support women throughout their menopause journey, Bonafide is on a mission to destigmatize the topic of menopause, which is often under-discussed…

Korian and Kamet Ventures Partner to Create and Accelerate Digital Health Solutions for Better Chronic Disease Management

Korian, a European services Group for elderly and fragile people, and Kamet Ventures, a European Venture builder with track-record in the digital health space are partnering to invent and co-build innovative solutions for better chronic diseases management.  Chronic diseases are a major public health challenge. Defined as long-term conditions with various levels of severity that may not have a cure, the diagnosis…

Sexual Wellness Startup Pique Launches with $4M in Seed Funding and an Offering Targeting Post-menopausal Women

Los Angeles-based Pique has raised $4M in seed funding led by Maveron to further build out and continue scaling accessible, effective, sexual health care solutions for women. The company launches its first offering today targeting post-menopausal women with a holistic solution that combines medical expertise with mental, physical, hormonal, and social factors to offer patients holistic, personalized care.  In the United States, 43% of…

Women’s Health Biotech Company Oviva Raises $11.5M in Seed Funding to Address Ovarian Aging

Women’s health biotech company Oviva Therapeutics has announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5M in seed funding, to develop first-in-class therapeutics to improve healthspan, the period of life spent in good health, in women. Oviva Therapeutics addresses the vast unmet need in women’s health by expanding funding, research, and clinical development of treatments…

Menopause Brand Womaness Is Now Sold at Ulta, the Largest Beauty Retailer in the U.S.

Menopause brand Womaness has announced a new partnership with Ulta Beauty, the largest beauty retailer in the U.S. Starting today, Womaness will be sold in select Ulta Beauty stores and online. The partnership signals an important moment in retail by providing access and visibility to items that cater specifically to the needs of the 40+ woman – an often overlooked segment. Womaness…

Celmatix Reaches a Key Preclinical Milestone in Its Premature Menopause Prevention Drug Program

We last spoke about Celmatix in January, when the company announced that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec has progressed into hit-identification. Now the company is back with more promising news and this time it’s about premature menopause. According to a release Celmatix has identified of a novel AMHR2 agonist compound that has demonstrated…